Carelink Acquires Fujifilm Flu Drug to Treat COVID-19 in China

Carelink, a Shanghai pharma founded in 2018, acquired China rights from Japan 's FujiFilm for Avigan ® Tablets (favipiravir), a flu drug, to treat COVID-19. Favipiravir is approved in several markets for the coronavirus, though not in the US or EU. Carelink will use FujiFilm's nonclinical and clinical data on Avigan for flu and COVID-19 as the basis for China approval of the drug. The two companies will also work together to develop an injectable form of Avigan. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.